United Kingdom
July 30, 2013

Plant Health Care (AIM: PHC), a leading provider of naturally derived products to the agriculture industry, announces that it has regained licensed rights to harpin αβ as a seed treatment. Plant Health Care and Monsanto have mutually agreed to discontinue the 2008 harpin αβ agreement which granted Monsanto certain exclusive rights to develop and sell harpin αβ as a seed treatment. Since the first usage in 2010, over 10,000,000 acres of harpin treated soybeans have been planted. Under the terms of this mutual agreement, all licensed rights have reverted back to PHC and PHC has purchased Monsanto’s remaining harpin inventory.

The agreement enables PHC to develop and sell harpin seed treatment into all crop markets, including corn, soybean, cotton, and canola, on a global basis.

Paul Schmidt, CEO at Plant Health Care, stated that “This agreement keeps the door open with Monsanto for their review of new technologies being developed within PHC, while enabling us to get closer to the market ourselves and to partner with others to fully exploit the potential of harpin as a seed treatment.”

Website: http://www.planthealthcare.co.uk

Published: July 30, 2013